(1 - 14 von 16
)
Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge...
www.finanznachrichten.de
Press Release 17 September Immunicum AB (publ) Announces Appointment of Pawel Kalinski and Inge Marie Svane to Scientific Advisory Board Immunicum AB …
Inge Marie Svane receives the Danish Cancer Society's Honorary Award
www.klinikum.uni-muenchen.de
Inge Marie Svane receives the Danish Cancer Society's Honorary Award Prof. Inge Marie Svane, who is with Prof. Per thor Straten one of the Directors of the Center for Cancer Immune Therapy in Copenhagen, received the yearly Honorary Award from the Danish Cancer Society. The Award was presented by HRH Crown Princess Mary of Denmark, for Inge Marie’s …
IO Biotech Announces Late-Breaking Oral Presentation of ...
www.wallstreet-online.de
These data will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress by Professor Inge Marie Svane, MD, …
IO Biotech raises 11 Million Euro in a Series A Financing Round |...
nordic9.com
In addition, Professor Inge Marie Svane, founder and director of Center for Cancer Immune Therapy at Herlev University Hospital, Denmark and Dr. Kapil Dhingra, an experienced non-executive biotech director will serve as advisors to the company.
News Detail - Lytix Biopharma
lytixbiopharma.com
The sarcoma study with LTX-315 in combination with Adoptive T cell Transfer (ATCT) is now open for patient recruitment. Edwin Klumper, CEO of Lytix Biopharma, expresses his thanks to the staff of the Center for Cancer Immune Therapy (CCIT) in Copenhagen led by Professor Inge Marie Svane and the Lytix staff all working jointly and diligently to achieve this milestone.
Immunicum : AB (publ) Announces Appointment of Pawel Kalinski ...www.marketscreener.com › ... › News › Summary
www.marketscreener.com
Inge Marie Svane, MD, PhD, joins Immunicum's Scientific Advisory Board with 25 years of research experience in cancer immunology and immunotherapy.
Immunicum AB (publ) Announces Appointment of Pawel Kalinski
www.globenewswire.com
— Inge Marie Svane, MD, PhD, joins Immunicum's Scientific Advisory Board with 25 years of research experience in cancer immunology and ... › ...
History of Changes for Study: NCT ClinicalTrials.govclinicaltrials.gov › history › NCT
clinicaltrials.gov
Sponsor: Inge Marie Svane. Responsible Party: Sponsor-Investigator Investigator: Inge Marie Svane. Official Title: Prof., MD. Affiliation: Herlev Hospital.
Study investigates potential of adoptive cell therapy in combination ...www.news-medical.net › news › Study-investigates-...
www.news-medical.net
· Dr. Inge Marie Svane, The National Center for Cancer Immune Therapy, Department of Oncology at Copenhagen University Hospital in Denmark.
History of Changes for Study: NCT ClinicalTrials.gov
clinicaltrials.gov
Investigator: Inge Marie Svane. Official Title: M.D., Professor. Affiliation: Herlev Hospital. Collaborators: Open or close this module Oversight ... Sponsor: Inge Marie Svane. Responsible Party: Sponsor-Investigator Investigator: Inge Marie Svane. Official Title: Prof., MD. Affiliation: Herlev Hospital. › history
Adoptive cell therapy in combination with checkpoint inhibitorswww.oncotarget.com › news › adoptive-cell-therapy...
www.oncotarget.com
· Inge Marie Svane from The National Center for Cancer Immune Therapy, Department of Oncology at Copenhagen University Hospital in Denmark said, " ...
Jette Larsen havde modermærkekræft, men i dag er sygdommen væk | Krop...
www.dr.dk
Ny behandlingsmetode med immunterapi gør modermærkekræft med spredning til den kræftform med flest behandlingsmuligheder.
TIL Therapy May Be the Curative Answer for Metastatic Melanomawww.oncnursingnews.com › view › til-therapy-may...
www.oncnursingnews.com
· ... has led to clinical responses in this population even after failure with checkpoint inhibitors, according to Inge Marie Svane, MD, PhD.
sortiert nach Relevanz / Datum